BIIB vs FULC
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. FULC: Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking gene expression to treat serious, rare genetic diseases.
Side-by-side fundamentals
| Metric | BIIB | FULC | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $202.95 | $3.58 | |
| Market cap as of 2026-08-03 | $30.0B | $273M | |
| P/E as of 2026-08-03 | 21.78 | n/a | |
| PEG as of 2026-08-03 | 10.99 | n/a | |
| Net margin as of 2026-08-03 | +13.8% | +8.1% | BIIB higher |
| Gross margin as of 2026-08-03 | +75.5% | n/a | |
| Operating margin as of 2026-08-03 | +17.5% | -3.6% | BIIB higher |
| ROE as of 2026-08-03 | +7.5% | -22.5% | BIIB higher |
| ROA as of 2026-08-03 | +4.7% | -21.2% | BIIB higher |
| Debt / equity as of 2026-08-03 | 0.34 | 0.00 | FULC lower |
| Revenue growth (YoY) as of 2026-08-03 | +1.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Beta as of 2026-08-03 | 0.48 | 1.34 | |
| 1-year return as of 2026-07-31 close | +58.6% | -46.8% | BIIB higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.